Objectives:To analyze psychological profiles, pain and oral symptoms in patients with oral lichen planus (OLP).Materials and methods: 300 patients with keratotic OLP (K-OLP; reticular, papular, plaque-like subtypes), 300 patients with predominant non-keratotic OLP (nK-OLP; erythematosus atrophic, erosive, ulcerative, bullous subtypes) and 300 controls were recruited in 15 universities. The number of oral sites involved and oral symptoms were recorded. The Numeric Rating Scale

A retrospective analysis was performed with the aim of understanding whether the risk factors showed in the literature for medication-related osteonecrosis of the jaws (MRONJ) in cancer patients are also relevant in osteoporotic patients taking antiresorptive drugs (ARDs). Data were retrospectively pooled from health records of patients on ARDs who requested a dental visit between January 2006 and April 2020 in the Dental Unit at Fondazione Ca’ Granda IRCCS Ospedale Maggiore Policlinico, University of Milan. A total of 434 patients were included. The following variables were collected: sex, age, smoking habit, type of ARD, duration of treatment, route of administration, therapeutic indication, concurrent systemic therapies and pathologies. Statistical analysis confirmed the relevance of chemotherapy, smoking, and immunosuppressive drugs as risk factors. In addition, a higher frequency of MRONJ in osteoporotic patients was reported in our cohort in association with an immunodeficiency disorder of variable origin. In conclusion, the identification of individual risk-profile before dental treatments is crucial for prevention. Anamnesis should include main risk factors, such as immunosuppression, dental extractions, smoking, trauma, and poor dental health. Nevertheless, our suggestion for dental professionals is to conduct a complete medical history of patients who mention long-term per oral therapies with ARDs for osteoporosis. Osteoporotic, as well as cancer patients, may also benefit from periodic monitoring of the ARDs therapy in order to prevent MRONJ.

Oral lichen planus (OLP) is an immune-mediated inflammatory disease of the oral mucosa characterized by a chronic condition. 1 It may appear with different clinical patterns ranging from keratotic manifestations (K-OLP, white reticular, papular, and/or plaque-like lesions), generally asymptomatic, to predominantly non-keratotic lesions (nK-OLP, atrophic, erythematous, erosive, ulcerative, and/or bullous lesions), 2 which may be symptomatic and impair quality of sleep (QoS), mood, and subsequently the quality of life of the affected patients.The occurrence of two most common sleep disturbances (SDs), insomnia, and daytime sleepiness, with or without mood disorders such as anxiety and depression, has been previously reported in OLP patients (OLPs). 3 However, only a few single center studies have investigated QoS, 4,5 this research based on limited samples, and no data are available in relation to the OLPs with different clinical patterns. Therefore, we aimed to perform a multicenter study in order to further analyze QoS, in a large cohort of OLPs analyzing differences between K-OLP and nK-OLP patterns. Moreover, to the best of our knowledge, this is the first study, which has assessed QoS in such a wide number of OLPs.The objectives of the present study were as follows:• to analyze the prevalence of insomnia and daytime sleepiness and their association with anxiety and depression in patients with keratotic OLP (K-OLPs) and patients with predominant non-keratotic OLP (nK-OLPs), in comparison with a control group of healthy subjects;• to investigate the correlation between poor sleep, anxiety and depression with the oral symptomatology of K-OLP and nK-OLP;• to validate the use of the Pittsburgh Sleep Quality Index (PSQI) in the screening of insomnia in OLPs. | ME THODS | ParticipantsAn observational multicenter case-control study was carried out between December 2018 and January 2020, in accordance with the ethical principles of the World Medical Association Declaration of

No abstract